Evolving Treatment Concepts and New Data in Advanced Prostate Cancer

STATEMENT OF NEED

Prostate cancer is the most common tumor type affecting men in the United States. It is estimated that 268,490 new cases were diagnosed and that 34,500 people died of prostate cancer in 2022 (Siegel et al, 2022). Prostate cancer alone accounts for 27% of all cancer diagnoses in men (ACS, 2022). To optimize outcomes for patients with prostate cancer, it is critical for health care providers to be familiar with the most recent evidence on therapy selection, biomarker testing, and the safety and efficacy of novel therapies for castration-sensitive prostate cancer (CSPC) and castration-resistant prostate cancer (CRPC). In this activity presented at the Society of Government Service Urologists James C. Kimbrough Urological Seminar, Tanya Dorff, MD, Section Chief of the Genitourinary Disease Program at City of Hope, provides expert guidance on evolving treatment paradigms in castration-sensitive and castration-resistant prostate cancer.

TARGET AUDIENCE

Military, academic, and private practice urologists, nurse practitioners, and physician assistants involved in the treatment of patients with prostate cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Distinguish biomarkers and clinical characteristics that can guide therapy selection for patients with prostate cancer
Assess practice guidelines on biomarker testing for patients with prostate cancer
Evaluate recent clinical trial findings on novel treatment strategies for metastatic castration-sensitive prostate cancer (CSPC)
Appraise emerging data on novel combination and sequential treatment strategies for nonmetastatic and metastatic castration-resistant prostate cancer (CRPC)